These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12942552)

  • 1. Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies.
    Markman M
    Cancer; 2003 Sep; 98(5):885-7. PubMed ID: 12942552
    [No Abstract]   [Full Text] [Related]  

  • 2. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacotherapy in ovarian carcinoma].
    Pfisterer J; Du Bois A
    MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of paclitaxel in the first line treatment of cancer of the ovary?].
    Slimane K
    Bull Cancer; 2003 Mar; 90(3):202-3. PubMed ID: 12803089
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.
    McGuire WP
    J Clin Oncol; 2009 Oct; 27(28):4633-4. PubMed ID: 19704055
    [No Abstract]   [Full Text] [Related]  

  • 9. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Informed consent in phase I trial].
    Shimada Y
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):226-30. PubMed ID: 8611051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical generalized granuloma annulare associated with two visceral cancers.
    Shimizu S; Yasui C; Tsuchiya K
    J Am Acad Dermatol; 2006 May; 54(5 Suppl):S236-8. PubMed ID: 16631952
    [No Abstract]   [Full Text] [Related]  

  • 12. [Advances in the treatment of ovarian carcinoma].
    Pfisterer J; du Bois A; Hilpert F; Wagner U; Meier W
    Dtsch Med Wochenschr; 2004 Feb; 129(8):379-84. PubMed ID: 14961446
    [No Abstract]   [Full Text] [Related]  

  • 13. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What determines whether patients are willing to participate in resuscitation studies requiring exception from informed consent?
    Abboud PA; Heard K; Al-Marshad AA; Lowenstein SR
    J Med Ethics; 2006 Aug; 32(8):468-72. PubMed ID: 16877627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of intraperitoneal chemotherapy in ovarian cancer.
    Markman M
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249
    [No Abstract]   [Full Text] [Related]  

  • 16. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
    J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
    Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
    J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of chemotherapy-responsive paraneoplastic rubral tremor.
    Kiriyama T; Hirano M; Kitauchi T; Saito K; Kataoka H; Ueno S
    Clin Neurol Neurosurg; 2011 Oct; 113(8):693-5. PubMed ID: 21616585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.